Parcom Capital acquires Viroclinics Biosciences
Viroclinics, founded in 2001 and specializing in testing new vaccines and drugs in the clinical trial stages prior to their market launch, has been acquired by Parcom Capital. Viroclinics has clients across the globe and conducts virology testing for clients that include the world’s top 10 biopharmaceutical companies. The company is also a market leader in the Netherlands. For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.
Bob van Gemen, CEO Viroclinics Biosciences, is pleased with the acquisition by Parcom Capital. “Our main focus at the moment is the research and treatment of respiratory viruses. We would like to broaden our portfolio, especially in the area of other viral targets, such as hepatitis, polio and RSV. For instance, we are very closely involved in a project that is on the verge of eradicating the polio virus for good. In Parcom Capital, we have found a new, solid partner who will enable us to realize even more of our ambitious targets. In the coming years, we will enter a new phase as a company and we have major growth ambitions.”
As a result of the sale, Viroclinics is now fully owned by Parcom Capital. Parcom has made several investments in successful Dutch companies in recent years, including the mobile telecom provider Simpel.nl, Star Group and RH Marine. “We see Viroclinics as a valuable addition to our portfolio,” said Parcom Capital partner Piet-Hein de Jager. “We believe very strongly in the growth opportunities for Viroclinics, which has acquired a leading position in the biopharma market with its expertise and innovative approach.”
Gilde Healthcare Service is the selling party and was advised in the acquisition process by William Blair. Parcom was advised by PricewaterhouseCoopers. The acquisition has no consequences for the employees of Viroclinics. The parties decline to publish any financial details.